Hoberman Kenneth

CIK: 0001573722
Director
Primary company: STEMLINE THERAPEUTICS INC (STML)

Hoberman Kenneth is a corporate insider at STEMLINE THERAPEUTICS INC (STML) filing SEC Form 4 transactions. 90 transactions across 3 companies, totaling $126,375 in purchases and $5,776,373 in sales. Source: SEC EDGAR.

AI Insider Summary

Insider trading profile for Hoberman Kenneth: PRINCIPAL = Stemline Therapeutics (STML, 73 tx, 2009-2020): 513,866 SELL vs 2,000 BUY = 257:1 ratio. Systematic distribution during Feb 2020 exit event: 600K A-code award at $0 + 1.37M U-code distribution + D-code 44K + D-code 25K + S-code liquidations at $4.91-$10.97 in Q1 2020 -- this is the STEMLINE tender-offer/exit conversion. Zero STML activity post-June 2020. Secondary = TG Therapeutics (TGTX, 12 tx, 2015-2026): 92,293 A-code acquisitions at $0 FMV spanning 2020-2026: 15K (Jun 2020), 20K (Jun 2021), 43.7K (Jul 2022), 20K (Sep 2023), 22.2K (Jun 2024), 14.7K (Jun 2025), 8.3K (Jun 2026) -- consistent annual/bi-annual grant receipts with no sells. Nuvectis Pharma (NVCT, 5 tx, 2022-2025): 51K A-code at $0 (15K Apr 2022 + 18K Jun 2023 + 30K Jun 2024 + 30K Jun 2025) + 6K P-code at $17.40 (May 2022) -- a small but fully discretionary open-market purchase at a deep early-stage valuation when the stock was a preclinical microcap. KEY SIGNAL: Post-STEMLINE exit, the insider rebuilt a concentrated gene-therapy/dermatology cluster (TGTX biotech success + NVCT deep-early-stage). The NVCT $17.40 P-code buy at a sub-$20 preclinical price ($17.40 × 6K = $104K personal commitment) is bullish on NVCT specifically. Classification: bullish on the TGTX/NVCT cluster; the STEMLINE history is exhausted and unrelated to current signal. Net: the A-code-only build-up across two overlapping oncology vehicles corroborates a personal-conviction allocation post-exit.

Total Transactions
90
Total Buy Value
$126K
Total Sell Value
$5.78M
Net Activity
$-5.65M
Last Transaction
Jun 2026
Companies
3

Companies

Transaction History

Source: SEC EDGAR Form 4 insider transaction filings.

Type
Award
Shares
8,325
Price
-
Value
-
Type
Award
Shares
14,718
Price
-
Value
-
Type
Award
Shares
30,000
Price
-
Value
-
Type
Award
Shares
22,250
Price
-
Value
-
Type
Award
Shares
30,000
Price
-
Value
-
Type
Award
Shares
20,000
Price
$0.00
Value
$0
Type
Award
Shares
18,000
Price
$0.00
Value
$0
Type
Award
Shares
43,732
Price
$0.00
Value
$0
Type
Purchase
Shares
6,000
Price
$17.40
Value
$104K
Type
Award
Shares
15,000
Price
$0.00
Value
$0
Type
Award
Shares
20,000
Price
$0.00
Value
$0
Type
Award
Shares
15,000
Price
$0.00
Value
$0
STEMLINE THERAPEUTICS INC
STML
Type
Disposition
Shares
44,058
Price
-
Value
-
STEMLINE THERAPEUTICS INC
STML
Type
Disposition
Shares
25,000
Price
-
Value
-
STEMLINE THERAPEUTICS INC
STML
Type
U
Shares
1,374,352
Price
-
Value
-
STEMLINE THERAPEUTICS INC
STML
Type
Award
Shares
600,000
Price
$0.00
Value
$0
STEMLINE THERAPEUTICS INC
STML
Type
Sale
Shares
16,704
Price
$4.91
Value
$82K
STEMLINE THERAPEUTICS INC
STML
Type
Sale
Shares
9,487
Price
$5.08
Value
$48K
STEMLINE THERAPEUTICS INC
STML
Type
Sale
Shares
11,547
Price
$6.42
Value
$74K
STEMLINE THERAPEUTICS INC
STML
Type
Award
Shares
208,417
Price
$0.00
Value
$0